Quantcast

Global Testicular Cancer Drugs Market 2014-2018

April 25, 2014

DUBLIN, Apr. 25, 2014 /PRNewswire/ – Research and Markets (http://www.researchandmarkets.com/research/dj4r99/global_testicular) has announced the addition of the “Global Testicular Cancer Drugs Market 2014-2018″ report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769



The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy.

Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient’s body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin).



According to the report, one of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer.



Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs.



The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Topics Covered:



01. Executive Summary



02. List of Abbreviations



03. Scope of the Report



04. Market Research Methodology



05. Introduction



06. Market Landscape



07. Testicular Cancer by Type



08. Testicular Cancer Disease by Stages



09. Treatment Options



10. Clinical Trial Snapshot



11. Geographical Segmentation



12. Buying Criteria



13. Rate of Incidence and Prevalence



14. Market Growth Drivers



15. Drivers and their Impact



16. Market Challenges



17. Impact of Drivers and Challenges



18. Market Trends



19. Trends and their Impact



20. Vendor Landscape



21. Key Vendor Analysis



22. Other Reports in this Series



Companies Mentioned:

    --  Bristol-Myers Squibb Co.
    --  Hospira Inc.
    --  Teva Pharmaceutical Industries Ltd.
    --  ZIOPHARM Oncology Inc.

For more information visit http://www.researchandmarkets.com/research/dj4r99/global_testicular

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus